Adamis Pharmaceuticals Corporation is a biopharmaceutical company that develops and commercializes specialty pharmaceutical and biotechnology products. The company focuses on products for respiratory disease, allergy, and opioid overdose. Its primary product candidates include Symjepi, a naloxone injection for the treatment of opioid overdose; Zimhi, an injection for the treatment of allergic reactions; and Tempol, a drug for the treatment of dermatological conditions. The company sells its products through distributors and pharmaceutical wholesalers in the United States.
Notification